Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin and Hydroxychloroquine in COVID-19
NCT05311813Completed
- Sponsor
- Beni Suef University
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of enoxaparin and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Beni Suef University. Primary endpoints: Time of undetectable viral RNA at 6 months, Duration of treatment at 6 months and 1 more. Started Jun 2021; status: completed.
02
Drugs
enoxaparinhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05311813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311813.